March 2026 was a turning point month for GLP-1 practices, with regulators, payers, and manufacturers all reshaping the rules at once
Cur-Res SLNs, formulated with Compritol 888 ATO lipid cores (average particle size 180.2 nm), achieved encapsulation efficiencies of 92% (CUR) and 62.8% (Res), with over 70% of the drug bound to the skin in transdermal experiments
Clinical trials enforce structured protocols that real-world patients may not follow
Do you often feel tired, foggy, or low on energyno matter how much you sleep
Help you apply for manufacturer PAPs if eligible
Semaglutide produces average weight loss of 14.9% of body weight in clinical trials, far exceeding what most people achieve through diet and exercise alone